Acumen Cash Conversion Cycle from 2010 to 2026
| ABOS Stock | USD 2.72 0.64 30.77% |
Cash Conversion Cycle | First Reported 2010-12-31 | Previous Quarter (37.11) | Current Value (35.26) | Quarterly Volatility 15.4575388 |
Check Acumen Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acumen Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 12.4 M, Interest Income of 17.3 M or Depreciation And Amortization of 152.2 K, as well as many indicators such as Price To Sales Ratio of 296, Dividend Yield of 0.0 or PTB Ratio of 0.54. Acumen financial statements analysis is a perfect complement when working with Acumen Pharmaceuticals Valuation or Volatility modules.
Acumen | Cash Conversion Cycle | Build AI portfolio with Acumen Stock |
Latest Acumen Pharmaceuticals' Cash Conversion Cycle Growth Pattern
Below is the plot of the Cash Conversion Cycle of Acumen Pharmaceuticals over the last few years. It is Acumen Pharmaceuticals' Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acumen Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cash Conversion Cycle | 10 Years Trend |
|
Cash Conversion Cycle |
| Timeline |
Acumen Cash Conversion Cycle Regression Statistics
| Arithmetic Mean | (13.43) | |
| Geometric Mean | 7.15 | |
| Coefficient Of Variation | (115.06) | |
| Mean Deviation | 14.22 | |
| Median | (3.04) | |
| Standard Deviation | 15.46 | |
| Sample Variance | 238.94 | |
| Range | 40.5795 | |
| R-Value | (0.81) | |
| Mean Square Error | 88.35 | |
| R-Squared | 0.65 | |
| Significance | 0.000086 | |
| Slope | (2.47) | |
| Total Sum of Squares | 3,823 |
Acumen Cash Conversion Cycle History
About Acumen Pharmaceuticals Financial Statements
Acumen Pharmaceuticals shareholders use historical fundamental indicators, such as Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although Acumen Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acumen Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acumen Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash Conversion Cycle | (37.11) | (35.26) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.